0000950159-22-000110.txt : 20220509 0000950159-22-000110.hdr.sgml : 20220509 20220509164540 ACCESSION NUMBER: 0000950159-22-000110 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220506 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220509 DATE AS OF CHANGE: 20220509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Corp CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 22905775 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K/A 1 cigna8k.htm CIGNA CORP. FORM 8-K
0001739940 true 0001739940 2022-05-06 2022-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K/A

Amendment No. 1

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 6, 2022

Cigna Corporation

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of incorporation)		 001-38769
(Commission File Number)		 82-4991898
(IRS Employer
Identification No.)

900 Cottage Grove Road

Bloomfield, Connecticut 06002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:

(860) 226-6000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.01 CI New York Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 
 

 

Explanatory Note

 

On May 6, 2022, Cigna Corporation issued a press release announcing its financial results for the quarter ended March 31, 2022, and filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission to furnish the press release. This Amendment No. 1 to the Current Report on Form 8-K/A is being filed solely to furnish the press release furnished in Item 9.01 of the Original 8-K as the press release does not appear in the Original 8-K on the SEC’s website. No other changes have been made to the Original 8-K.

 

Item 2.02Results of Operations and Financial Condition.

 

On May 6, 2022, Cigna Corporation issued a press release announcing results for the three months ended March 31, 2022. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

  

Exhibit No.Description

 

99.1Press release dated May 6, 2022.

 

104Cover Page Interactive Data File (embedded within the Inline XBRL).
 
 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Cigna Corporation

Date:  May 9, 2022 By: /s/ Brian C. Evanko
    Brian C. Evanko
    Executive Vice President and Chief Financial Officer
     
     

 

 EX-99.1 2 ex99-1.htm EXHIBIT 99.1

 

 

Exhibit 99.1

 

 

Press Release

 

INVESTOR RELATIONS CONTACT:

Ralph Giacobbe

860-787-7968

Ralph.Giacobbe@cigna.com

 

MEDIA CONTACT:

Justine Sessions

860-810-6523

Justine.Sessions@cigna.com

 

 

 

Cigna Reports Strong First Quarter 2022 Results, Raises 2022 Outlook

 

•Total revenues in the first quarter were $44.0 billion, and adjusted revenues1 were $44.1 billion
•Shareholders’ net income for the first quarter was $1.2 billion, or $3.68 per share
•Adjusted income from operations2 for the first quarter was $1.9 billion, or $6.01 per share
•Adjusted income from operations2,3 for 2022 is now projected to be at least $22.60 per share3

 

BLOOMFIELD, CT, May 6, 2022 – Global health services company Cigna Corporation (NYSE: CI) today reported strong first quarter 2022 results reflecting revenue and earnings growth across its businesses.

 

“We’ve had a strong start to the year as we advance our growth strategy and support the health and well-being of our clients and customers,” said David M. Cordani, chairman and chief executive officer. “We’re taking decisive steps forward with innovation, new partnerships and re-investing in our company so we can achieve greater impact for the customers and communities we’re privileged to serve.”

 

Total revenues for first quarter 2022 were $44.0 billion. Adjusted revenues1 were $44.1 billion and reflect strong contributions from each of Cigna's ongoing businesses.

 

Shareholders’ net income for first quarter 2022 was $1.2 billion, or $3.68 per share, compared with $1.2 billion, or $3.30 per share, for first quarter 2021.

 

Cigna's adjusted income from operations2 for first quarter 2022 was $1.9 billion, or $6.01 per share, compared with $1.7 billion, or $4.73 per share, for first quarter 2021 reflecting strong earnings contributions across the Company’s businesses.

 

Reconciliations of total revenues to adjusted revenues1 and of shareholders’ net income to adjusted income from operations2 are provided on the following page and on Exhibit 1 of this earnings release.

 
2 

 

CONSOLIDATED HIGHLIGHTS

 

The following table includes highlights of results and reconciliations of total revenues to adjusted revenues1 and shareholders’ net income to adjusted income from operations2:

Consolidated Financial Results (dollars in millions):
   Three Months Ended
   March 31,  December 31,
   2022  2021  2021
          
Total Revenues  $44,005   $40,971   $45,688 
Net Realized Investment (Gains) Losses from Equity Method Investments1   103    14    (12)
Adjusted Revenues1  $44,108   $40,985   $45,676 
                
Consolidated Earnings, net of taxes               
Shareholders’ Net Income  $1,183   $1,161   $1,116 
Net Realized Investment (Gains) Losses2   355    13    (59)
Amortization of Acquired Intangible Assets2   356    388    326 
Special Items2   37    102    189 
Adjusted Income from Operations2  $1,931   $1,664   $1,572 
                
Shareholders’ Net Income, per share   $3.68   $3.30   $3.39 
Adjusted Income from Operations2, per share  $6.01   $4.73   $4.77 

 

 

•Year to date through May 5, 2022, the Company repurchased 7.6 million shares of common stock for approximately $1.8 billion.

 

•The debt-to-capitalization ratio was 41.9% at March 31, 2022, in line with fourth quarter 2021.

 

•The adjusted SG&A expense ratio4 was 7.4% for first quarter 2022 compared to 8.0% for first quarter 2021, driven by revenue growth and continued expense efficiency.

 

 

 
3 

 

CUSTOMER RELATIONSHIPS

 

The following table summarizes Cigna’s medical customers and overall customer relationships:

 

Customer Relationships (in thousands):

   As of the Periods Ended
   March 31,  December 31,   
   2022  2021  2021   
          
Total Customer Relationships5   190,370    177,607    185,672 
                
Total Pharmacy Customers   107,440    101,002    107,298 
                
U.S. Commercial   14,621    13,552    13,854 
U.S. Government   1,402    1,464    1,510 
International Health   1,756    1,655    1,717 
Total Medical Customers5,6   17,779    16,671    17,081 
                
Behavioral Care   44,078    38,950    40,380 
Dental   18,169    17,800    17,731 
Medicare Part D   2,904    3,184    3,182 

 

 

•Total customer relationships5 at first quarter 2022 grew by 3% year to date to 190.4 million.

 

•The total medical customer base5,6 at first quarter 2022 grew to 17.8 million, an increase of 698,000 customers year to date, driven by growth in U.S. Commercial fee-based client relationships, partially offset by a decrease in U.S. Government inclusive of the divestiture of the Medicaid business.
 
4 

 

HIGHLIGHTS OF SEGMENT RESULTS

 

See Exhibit 1 for a reconciliation of adjusted income (loss) from operations2 to shareholders’ net income.

 

Evernorth

 

This segment includes a broad range of coordinated and point solution health services and capabilities, including pharmacy solutions, benefits management solutions, care delivery and care management solutions, and intelligence solutions, which are provided to health plans, employers, government organizations, and health care providers.

 

Financial Results (dollars in millions):
   Three Months Ended
   March 31,  December 31,
   2022  2021  2021
          
Adjusted Revenues1   $33,586   $30,620   $35,086 
Adjusted Income from Operations, Pre-Tax2   $1,302   $1,223   $1,634 
Adjusted Margin, Pre-Tax7   3.9%   4.0%   4.7%

 

•First quarter 2022 adjusted revenues1 increased 10% relative to first quarter 2021 reflecting strong organic growth in specialty pharmacy services.

 

•First quarter 2022 adjusted income from operations, pre-tax2 increased 6% relative to first quarter 2021, reflecting continued affordability improvements and business growth, partially offset by strategic investments in expanding our services portfolio and digital capabilities.
 
5 

 

Cigna Healthcare6

 

This segment includes Cigna’s U.S. Commercial, U.S. Government, and International Health businesses that provide comprehensive medical and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services for insured and self-insured customers. U.S. Government solutions include Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, and individual health insurance plans both on and off the public exchanges. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.

 

Financial Results (dollars in millions):   
   Three Months Ended
   March 31,  December 31,
   2022  2021  2021
          
Adjusted Revenues1,8  $11,392   $11,067   $11,214 
Adjusted Income from Operations, Pre-Tax2  $1,279   $1,042   $472 
Adjusted Margin, Pre-Tax7   11.2%   9.4%   4.2%

 

•First quarter 2022 adjusted revenues1,8 grew 3% over first quarter 2021, reflecting increased specialty contributions and premium increases to cover underlying cost trends, partially offset by the divestiture of the Medicaid business.

 

•First quarter 2022 adjusted income from operations, pre-tax2 and adjusted margin, pre-tax7 increased relative to first quarter 2021 primarily due to increased specialty contributions.

 

•The Cigna Healthcare MCR4 of 81.5% for first quarter 2022 compares to 80.9% for first quarter 2021, reflecting risk adjustment updates related to prior years and higher medical costs in the Individual business, partially offset by lower direct COVID-19 costs.

 

•Cigna Healthcare net medical costs payable9 was $4.29 billion at March 31, 2022, $3.79 billion at March 31, 2021, and $4.00 billion at December 31, 2021. Favorable prior year reserve development on a gross pre-tax basis was $276 million and $233 million through first quarter 2022 and 2021, respectively.

 

 

 

 

 

 

 

 
6 

 

Corporate and Other Operations6

 

Corporate reflects interest expense, as well as amounts not allocated to operating segments and includes intersegment eliminations. Additionally, this discussion includes items reported in Other Operations which is comprised of the international life, accident, and supplemental benefits businesses held for sale pending divestiture6, Corporate Owned Life Insurance (“COLI”), our interest in a joint venture in Turkey and the Company’s run-off operations.

 

Financial Results (dollars in millions):
   Three Months Ended
   March 31,  December 31,
   2022  2021  2021
                
Adjusted (Loss) from Operations, Pre-Tax2  $(117)  $(123)  $(115)

 

•First quarter 2022 adjusted loss from operations, pre-tax2 was favorable to first quarter 2021 primarily reflecting lower interest expense.

 

 
7 

 

2022 OUTLOOK

 

Cigna's outlook for full year 2022 adjusted revenues1,3 is projected to be at least $177 billion. Cigna’s outlook for full year 2022 consolidated adjusted income from operations2,3 is projected to be at least $7.05 billion, or at least $22.60 per share3. Additionally, this outlook includes the impact of expected future share repurchases, anticipated 2022 dividends, and assumes that the previously announced divestiture of our international life, accident, and supplemental benefits businesses6 will close in the second quarter of 2022.

(dollars in millions, except where noted and per share amounts)
2022 Consolidated Metrics

Projection for Full Year Ending

December 31, 2022

Change from

Prior Projection

Adjusted Revenues1,3 at least $177,000  
Adjusted Income from Operations2,3 at least $7,050 +$100
Adjusted Income from Operations, per share2,3 at least $22.60 +$0.20
Adjusted SG&A Expense Ratio3,4 6.9% to 7.3%  
Adjusted Tax Rate3,10 22.0% to 22.5%  
Cash Flow from Operations3 at least $8,250  
Weighted Average Shares Outstanding (millions)3 310 to 314 ‘+2.0 at the midpoint
     
2022 Evernorth Metrics    
Adjusted Income from Operations, Pre-Tax2,3 ~$6,100  
     
2022 Cigna Healthcare Metrics    
Adjusted Income from Operations, Pre-Tax2,3 ~$3,950 +$50
Medical Care Ratio3,4 82.0% to 83.5%  
Total Medical Customer Growth (lives)3,5 at least 725,000 ‘+150,000

 

 
8 

 

The foregoing statements represent the Company’s current estimates of Cigna's 2022 consolidated and segment adjusted income from operations2,3 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

 

This quarterly earnings release and the Quarterly Financial Supplement are available on Cigna’s website in the Investor Relations section (https://investors.cigna.com/home/default.aspx). Management will be hosting a conference call to review first quarter 2022 results and discuss full year 2022 outlook beginning today at 8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of Cigna's website located at https://investors.cigna.com/events-and-presentations/default.aspx.

 

The call-in numbers for the conference call are as follows:

Live Call

(888) 455-5036 (Domestic)

(773) 799-3981 (International)

Passcode: 562022

 

Replay

(866) 357-1405 (Domestic)

(203) 369-0111 (International)

 

It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.

 

 

About Cigna

 

Cigna Corporation (NYSE: CI) is a global health services company dedicated to improving the health, well-being and peace of mind of those we serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth companies or their affiliates, and Express Scripts companies or their affiliates. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and other related products.

 

Cigna maintains sales capability in over 30 countries and jurisdictions, and has over 190 million customer relationships throughout the world. To learn more about Cigna®, including links to follow us on Facebook or Twitter, visit www.cigna.com.

 

 

Notes:

 

1.Adjusted revenues is used by Cigna’s management because it permits analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of consolidated adjusted revenues to total revenues.
 
9 

 

 

2.Adjusted income (loss) from operations is a principal financial measure of profitability used by Cigna’s management because it presents the underlying results of operations of Cigna’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income from operations is defined as shareholders’ net income (or income before income taxes less pre-tax income/loss attributable to noncontrolling interests for the segment metric) excluding net realized investment results, amortization of acquired intangible assets and special items. Cigna’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a reconciliation of consolidated adjusted income from operations to shareholders’ net income.

 

3.Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income (loss) or adjusted revenues to total revenues on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof including (i) future net realized investment results (from equity method investments with respect to adjusted revenues) and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond Cigna’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

 

The Company’s outlook assumes that the previously announced divestiture of the international life, accident, and supplemental benefits businesses6 will close in the second quarter of 2022 but excludes the potential effects of any other business combinations that may occur after the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2022 dividends.

 

As announced in January 2021, Cigna currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board’s determination that the declaration of dividends remains in the best interests of Cigna and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

 

The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

 

 
10 

 

 

4.Operating ratios are defined as follows:
•The Cigna Healthcare medical care ratio represents medical costs as a percentage of premiums for all U.S. Commercial risk products, including medical, pharmacy, dental, stop loss and behavioral products provided through guaranteed cost or experience-rated funding arrangements, as well as Medicare Advantage, Medicare Part D, Medicare Supplement, individual on and off-exchange products, and health care products within our International Health business, within the Cigna Healthcare segment.
•Adjusted SG&A expense ratio represents enterprise selling, general and administrative expenses excluding special items as a percentage of adjusted revenue at a consolidated level.

 

5.Customer relationships are defined as follows:
•Total medical customers includes individuals in the Cigna Healthcare segment who meet any one of the following criteria: are covered under a medical insurance policy, managed care arrangement, or service agreement issued by Cigna; have access to Cigna's provider network for covered services under their medical plan; or have medical claims and services that are administered by Cigna.
•Prior year lives include the Medicaid customers which was divested on January 1, 2022.
•International Health medical customers excludes medical customers served by less than 100% owned subsidiaries and customers that are part of the businesses to be sold pursuant to the previously announced divestiture of the international life, accident, and supplemental benefits businesses6. Prior year lives have been restated to conform to this presentation.
•Policies issued by the businesses subject to the definitive agreement to sell certain of our international life, accident, and supplemental benefits businesses6 and our joint venture in Turkey have been excluded from customer relationships.

 

6.We entered into a definitive agreement in October 2021 to sell our life, accident, and supplemental benefits businesses in several countries to Chubb INA Holdings, Inc. (“Chubb”). As of March 31, 2022 we now expect to sell our life, accident, and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) to Chubb for $5.72 billion in cash (the “Chubb Transaction”); we no longer expect to sell our interest in a joint venture in Turkey as part of the Chubb Transaction. Subject to applicable regulatory approvals and customary closing conditions, we expect to complete this transaction in the second quarter of 2022.

 

In connection with the pending Chubb Transaction, we revised our business reporting structure. As such we adjusted our segment reporting effective in the fourth quarter of 2021 and segment results for the three months ended March 31, 2021 have been restated to conform to the new segment presentation. See Cigna’s Current Report on Form 8-K filed on January 24, 2022 for additional information.

 

7.Adjusted margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.

 

8.Cigna owns a 50% noncontrolling interest in its China joint venture. As such, the adjusted revenues for the Cigna Healthcare segment only include Cigna’s 50% share of the joint venture’s earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.

 

9.Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other recoverables. The gross medical costs payable balance was $4.49 billion as of March 31, 2022, $4.26 billion as of December 31, 2021, and $4.03 billion as of March 31, 2021.

 

 
11 

 

 

 

10.The measure “adjusted tax rate” is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, “consolidated effective tax rate”. We define adjusted tax rate as the consolidated income tax rate applicable to the Company’s pre-tax income excluding pre-tax income/loss attributable to noncontrolling interests, excluding net realized investment results, amortization of acquired intangible assets, and special items. Cigna’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Management is not able to provide a reconciliation to the consolidated effective tax rate on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof include (i) future net realized investment results and (ii) future special items.

 

 

 

 

 

 

 
12 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2022 on a consolidated, per share, and segment basis; projected adjusted revenue outlook for 2022; projected total medical customer growth over year end 2021; projected medical care and adjusted SG&A expense ratios; projected consolidated adjusted tax rate; projected cash flow from operations; future dividends; projected weighted average shares outstanding; future financial or operating performance, including our ability to deliver affordable, personalized and innovative solutions for our customers and clients, including in light of the challenges presented by the COVID-19 pandemic; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of the developing inflationary pressures; the ongoing Russia-Ukraine conflict; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions, including the sale of our international life, accident and supplemental benefits businesses; and other statements regarding Cigna’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; the scale, scope and duration of the COVID-19 pandemic and its potential impact on our business, operating results, cash flows or financial condition; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations; risks related to strategic transactions and realization of the expected benefits of such transactions, including with respect to the sale of our international life, accident and supplemental benefits businesses, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits and investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, stock market or interest rate declines and risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; unfavorable industry, economic or political conditions; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-K, 10-Q and 8-K available through the Investor Relations section of www.cigna.com. You should not place undue reliance on forward-looking statements, which speak

 
13 

 

only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

 

 

 

 

 

 

 

 

 

 

 
 

 

CIGNA CORPORATION  Exhibit 1
COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)
(Dollars in millions, except per share amounts)
   Three Months Ended  Three Months Ended
   March 31,  December 31,
   2022  2021  2021
          
REVENUES               
                
Pharmacy revenues  $30,697   $28,025   $32,328 
Premiums   10,356    10,214    10,342 
Fees and other revenues   2,538    2,341    2,638 
Net investment income   414    391    380 
Total Revenues   44,005    40,971    45,688 
Net realized investment results from certain equity method investments   103    14    (12)
Adjusted revenues (1)  $44,108   $40,985   $45,676 
                
SHAREHOLDERS’ NET INCOME               
                
Shareholders' net income  $1,183   $1,161   $1,116 
After-tax adjustments to reconcile adjusted income from operations               
Net realized investment (gains) losses (2)   355    13    (59)
Amortization of acquired intangible assets   356    388    326 
Special Items               
Integration and transaction-related costs   37    22    70 
Debt extinguishment costs   —      101    —   
(Benefits) charges associated with litigation matters   —      (21)   —   
Charge for organizational efficiency plan   —      —      119 
Adjusted income from operations  $1,931   $1,664   $1,572 
                
Pre-tax adjusted income (loss) from operations by segment               
Evernorth  $1,302   $1,223   $1,634 
Cigna Healthcare   1,279    1,042    472 
Corporate and Other Operations   (117)   (123)   (115)
Consolidated pre-tax adjusted income from operations   2,464    2,142    1,991 
    Adjusted income tax expense   (533)   (478)   (419)
Consolidated after-tax adjusted income from operations  $1,931   $1,664   $1,572 
                
DILUTED EARNINGS PER SHARE               
                
Shareholders’ net income  $3.68   $3.30   $3.39 
After-tax adjustments to reconcile to adjusted income from operations               
Net realized investment (gains) losses (2)   1.10    0.04    (0.18)
Amortization of acquired intangible assets   1.11    1.10    0.99 
Special items               
Integration and transaction-related costs   0.12    0.06    0.21 
Debt extinguishment costs   —      0.29    —   
(Benefits) charges associated with litigation matters   —      (0.06)   —   
Charge for organizational efficiency plan   —      —      0.36 
Adjusted income from operations (3)  $6.01   $4.73   $4.77 
Weighted average shares (in thousands)   321,282    351,976    329,641 
Common shares outstanding (in thousands)   318,502    344,454    322,948 
                
SHAREHOLDERS' EQUITY at March 31,  $46,087   $48,149      
                
SHAREHOLDERS' EQUITY PER SHARE at March 31,  $144.70   $139.78      

 

(1) Adjusted revenues is defined as total revenues excluding the following adjustments: special items and Cigna’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of past or future underlying performance of our businesses.

 

(2) Includes the Company’s share of certain realized investments results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.

 

(3) Adjusted income (loss) from operations is defined as shareholders’ net income (or income before income taxes less pre-tax income/loss attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net realized investment results, amortization of acquired intangible assets and special items. Cigna’s share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.

 

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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ci-20220506.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ci-20220506_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ci-20220506_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 06, 2022
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description On May 6, 2022, Cigna Corporation issued a press release announcing its financial results for the quarter ended March 31, 2022, and filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission to furnish the press release. This Amendment No. 1 to the Current Report on Form 8-K/A is being filed solely to furnish the press release furnished in Item 9.01 of the Original 8-K as the press release does not appear in the Original 8-K on the SEC’s website. No other changes have been made to the Original 8-K.
Document Period End Date May 06, 2022
Entity File Number 001-38769
Entity Registrant Name Cigna Corporation
Entity Central Index Key 0001739940
Entity Tax Identification Number 82-4991898
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 900 Cottage Grove Road
Entity Address, City or Town Bloomfield
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06002
City Area Code (860)
Local Phone Number 226-6000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01
Trading Symbol CI
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 cigna8k_htm.xml IDEA: XBRL DOCUMENT 0001739940 2022-05-06 2022-05-06 iso4217:USD shares iso4217:USD shares 0001739940 true 8-K/A 2022-05-06 Cigna Corporation DE 001-38769 82-4991898 900 Cottage Grove Road Bloomfield CT 06002 (860) 226-6000 false false false false Common Stock, Par Value $0.01 CI NYSE false On May 6, 2022, Cigna Corporation issued a press release announcing its financial results for the quarter ended March 31, 2022, and filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission to furnish the press release. This Amendment No. 1 to the Current Report on Form 8-K/A is being filed solely to furnish the press release furnished in Item 9.01 of the Original 8-K as the press release does not appear in the Original 8-K on the SEC’s website. No other changes have been made to the Original 8-K. EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cigna.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cigna8k.htm ci-20220506.xsd ci-20220506_lab.xml ci-20220506_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cigna8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cigna8k.htm" ] }, "labelLink": { "local": [ "ci-20220506_lab.xml" ] }, "presentationLink": { "local": [ "ci-20220506_pre.xml" ] }, "schema": { "local": [ "ci-20220506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CI", "nsuri": "http://cigna.com/20220506", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cigna8k.htm", "contextRef": "From2022-05-06to2022-05-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cigna.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cigna8k.htm", "contextRef": "From2022-05-06to2022-05-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cigna.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0000950159-22-000110-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950159-22-000110-xbrl.zip M4$L#!!0 ( *^%J53$U8VM(@, )P+ / 8VDM,C R,C U,#8N>'-D MM57;;AHQ$'UNI?Z#N^_>"P@:""2J2)/0D#2")DKS4AFO(19>>VM[N?Q][;UP MAP)1]\F>.>?,C#WC;5Q.(P;&1"HJ>-,)7-\!A&,14CYL.D\]^+77:K<=<'GQ MZ2,P7^,SA.":$A;6P97 L,T'XAP\H(C4P0WA1"(MY#EX1BRQ%G%-&9&@):*8 M$4V,(XM4!Q4W*", X0&ZSX2'0CYUVW/=-ZUC5?>\R63BON >^CNVQU^U+-*MXQ^ MC:;CF[C41Z/J[>PLJM%JC=/7%O9)=(_;W[.0#87?2(2 N0RNFHZM+R]O4G:% M''HEWP^\E_M.+\4Y&; ^992/MLJWFI=X"NH&<]B4KI,N>=?>1(G-EXZ5[ M\)0KC3A>P8=Z3E@&5[S,N0*E6Z'5#$H+:$C6<(I@=RC&GG$8?*E4 !,%APC% M<_ J7XJFCM6P$KJ3: QKH.@GL5$;85FKA5"JSU'8CKDR+9C"O K?M4,%2,1 MX?I:R.B*#%#"3 Y_$L3H@)+0 1K)(=&VOU2,,-DG570HXER81C;3E%NL+8ZI MZ51C^-"P5UJ7@I&?)E=@%V:$M@A;C]<2Y@UP V;3K:T$D8P%0G)@'*:1LH' M)0#0CD5B2S++E-+PUL%+$HDBX0]^D:YC293AI:EWC"$GYI =)(P83MAQG$4J M6RFYH3BBQ:$5P] E Y .4=U>=]-1U#YC3FY[DV30=#"%Q M,T+IN:^?11ZVD$ 2;ZALC+@1$3&1FIJ.7)KC+'&J+?UQ*0RP<90#O/<7S%#_ MV((-A;#_6&G'ZB^7F$^&MQB-?+\^/@U3K) :\(TAW/?\90]W1^!4:@_%[F#! M@]8$@Q(L!^Y4A8M,CTEB<0+')5'P3DABQR.\+;[:!;>+M(4.#;KC,=\;="O' M(TRKPG)R"LM/_SMR2&6.2F+E.D,M/2MA17WH![ 4[$[G7\QTKTYJ BP2KN7L MF$98IA2;TVYC\=,^["(*?'8)]C]^:M@3NF S^+86:'B9FEG^!5!+ P04 M" "OA:E4O^K2D/T* " A@ $P &-I+3(P,C(P-3 V7VQA8BYX;6S-G5UO MX[@5AN\+]#]PW9L6&,<3!RV0[&07&4^R,#:;9&//;-M%L: EQA%"DP$E)_:_ M+RF)LD3Q2$J*DIR+&8_X'NJE^)BDOHX__;C;4/1"1)IP=CXZ/OHX0H1%/$[8 M^GST=3&^6,SF\Q%*,\QB3#DCYR/&1S_^\.<_(?GGTW?C,;I*"(W/T!<>C>?L M@7^/;O"&G*&?"","9UQ\C[YANE5;^%5"B4 SOGFF)".RH-CQ&?K[T?$)1N/Q M@'J_$19S\?5^7M7[F&7/Z=ED\OKZ>L3X"W[EXBD]BOAF6(6+#&?;M*KMX^YC M^:<(_T03]G2F_EKAE"!YO%AZMDN3\Y':;[G;UY,C+M:3Z<>/QY-__G*]B![) M!H\3IHY;1$8Z2M5BBSL^/3V=Y*5:VE+N5H+J?9Q,M)VJ9EF:=.AK3M+D+,WM M7?,(9WFW]^X&@0KUO[&6C=6F\?%T?')\M$OCD3[X^1$4G))[\H#R9IYE^V>) M4IHH$D;EMD=!'NQFJ! 3%3]A9(TS$JL=G:H='?]#[>@OY>9KO")TA)12\@&V MZ[115QDT<6WVCHB$QY?L?:[-:$_VY7='9/]# ^KQSINPY!FF[S)?CW1N^X:\ M[X@?XMP?:3G.D_<=Z5KD_\5VUK;\YL-K/ZY4;;R6GQH6R2Z3$QB)M4E51<<( MG.\AGQC*NJO:>=2HEZK1G(MVV]7,F->9DNAHS5\F,4EDW=.I^C!6'_)FR__\ M,>-R)7"Q2C.!HTS7E#?C?&0IGYB6E/)":%]81#V-*Q63B,NIZ3D;T^(P%N$/ M@F^LNRU;S2V%?]!5%5\<%KD+P&A#)DC*MR(B;^J5NEOH*)6.-E0JU)**L/'7 MQ>B'7(-^UZK_?)H<:G'0T7()M-T0EBUEC986-(M==;/-E.[E>ED0G6PQ9/:Q MEB"E<=S!%W+'L=KY%<5KBWVCW%476VWI/FX4!M')-D=F+U<:I$2^NOD+22.1 M/*OE?%<[&C+GG6XQV>K[FB8L!-K&8!)J6D\#^SU9)VIJ41;4^2U1&SN&,4#O M>NCOM&W.!59Q$- ,<0C.%O4@5$5YXNB"L2VF]^29BRY\FC+7U-A,FK#4-4$Q M8C$&HE%H42'V1,2O6WG&3@3=]T+14KKF K!JHF'(@J+#[@T$I)+[960I,$L3 M-8#U0M*6.C_= ,RV3CT,75"< .;@4Y)*[Y>4Q2.A5-T/P*Q_0+&)7=,"&S9Y M:2N#(@:T!S*31Z R)!QL+E_4ZEPNDP8VMJ;W"4_+=A<_E3A8A$R' RG*PY"* M\T12[39$#T,MI6MZ *LF-X8L*&+LWD!6"CG*]?XAN63Q($0JG1] #)MV/$I1 M@' TG?6A(=4^P;A*T@C3PLN5W)9V-,^B=0T(:->$I"4,"A3('0A+$:"9R4.\ M O,O@L4P7&I*/["TK-I1J60!@F)ZZ\-$Z;U ,ML*T7 -SSBPU-E-V1ZSU?U9 M0!<$*#WF6G=M"WD#%$\ST"7+DFROGJ>[V6Y61%@:UY:X8@,RIYDPRX-@ 3!E M,E#(D-*A0NBEY_5= I:IAQC!YI@RMP38338I:&H"(L%J#*#AH,V?*?5"Q$R. M3 +3.8O)[F>R!]O5TKEE K#9A,(0!42%W1F 12E&N1I)N1 MJ:(M=(L&9+3)AJD*" [ &D!'J4:+^DN)Y\!Y*0+U;6'IL M-YD!Q &AT^T0($@&H6:43Y#F+.+BF=<>=YCQK1P ]S,>PRN4GBBW4 UJ0A.M MSI" !OB$\"L$?JA>"8%3UX!4C5X(>XBCN6!2LM_KA-&CL'V6[5NZ>JP MVV3*(@R()-@=P$^I_* _(!6#;EDHT$S?T-2I?VBF0Z&9!@W-]#W0+%]Y(-"< MO*&I)_ZA.1D*S4G0T)R\"QK9\5['FIG\>"N6_-7V<#:H](),VZH5F(,L/%Q: MWOI@40%J/:-"?&*2+ZQNQ9W@+PF+X"4S)/<"#&#:2HVA#0\=N\$^?JH%L8[S M.M84B_+>+XF6^1EEFB;M0TRA"0^2IK'>P:50^T3BCJ<9IO].GCM/Q.UB+WA8 M#5LA:2C#0\5FKP^8(@;)(!\GUB6NZH:&]54RH]S=*\ 66X=7@&N%04!@<]1^ M!;BX>E*(7'>S8E00#(P(S6)GG6PQ5?5QK2R,+FX;:O5P_KV6&A]?9)7=A=X] M<@8_(-"6N.IIR)SN;;,\B!X'3)F]GLM0KO-T-5YEF$CMPW>MS-G,;MJI)G)= M$$3OFFY:T[0N=]R;OXDDDWN>\[G)DD ME%K4%#O&8L%I$B59PM:_R)-/D6!;JVPB5T# !C4-;440*("V3 X.0J25CB&X M$T1!2&1'Y"\!JL1"XO;AP3K;=XE=0=%O6,,!*X. I->>"8L,&$>U"%2$H#S& M+S;S--T2\29X+"&>$ +- R"U]"'B!)GLA:H(],G6@D1;.3_NCZ>K99)1V\EE M6^)L3@+,53.241X$&X IDX6\#/$'=#S]Z^IO2$O+W^AK3T/^Y2YZE*8(\$*"7>9ZZ+>9-(?_NB8(!#J,M4Y*2BG26A\O)!RF MK'7_(F#M;1&P[ED$K$-K=%BA Y+MVN:++&0'+"3K5K*#HL MFWQ8I$&A OL#QXPJ!!UB7&>TS%.D;IUN689&_2RYL(Q.@P/9"$96G+T-24H>R3HLOP9NGHF^*(>7[\T$D7J MA8AB5DBD ZQ#$UMY)A43^/RTW, M,[(!WW;H#W%%T%#SFJ,^?1 T#31I,I6'-4^N\T"D(GUF,ZHGMX>7> V1XY6Q MQ:"Q,*XI@F $M 4MB^N_%> G=]YV19/HBG(,7V5I:!QGS&O;,Y+E'00!$=!V M!:7(RX4H5WKI_\^8/8GM M&- XR9#1T1 Z VP"=UPR"-1'OH!%<&H%NWI_"P]9 $D\>?]/7D@0KUWL"2[ M[+/%;W4*G>BFJ5X!6ZAFQL@KTNZH$Y;78 M?K^\ONE:?I*;]2;YUPJG1&[Y+U!+ P04 " "OA:E4A59@55(' #-5P M$P &-I+3(P,C(P-3 V7W!R92YX;6S-G%USXC84AN\[T__@TFL@D.ZVR2;M M)&S883:[24-VM^W-CK %:")+C"0'^/>5;,SR8MB(I8)DS,+EM?QNVK\6 T:D7:$)$0+@6]; G9^NO/ MGW^*[,_%+^UV-&24)^?1>QFW1V(JWT6?24K/HP]44$6,5.^BKX1G;HL<,DY5 M-)#I@E-#[1=%P^?1FT[OE$3M-J#>KU0D4GUY&&WKG1NST.?=[G*Y[ CY3)92 M/>E.+%-8A6-#3*:WM9VL3C8_1?$+SL33N?LU(9I&EI?0YRO-+ENNW4VSR].. M5+-N_^2DU_WGT^TXGM.4M)EPW&+:*DNY6JK*]<[.SKKYMZ7T2+F:*%ZV<=HM MN[.MV7[+ OJ=GFAVKO/NW9*SJ];,7,5MSOG[PY>>NJ M_75/8M8+NT]JYG:I5M3=:W*AJ*;"Y"YO[8:](G1E[)Y$D[(BUSJH4X89I]SL M)+VH[?:H++4-V8^%'K@L]^*?=?<@A MY #L/]_SAJXFVB@2F[(F3B:4Y_5_MYH#2;>!7I4D'FV-U9W:5QSV:3=B5RJ. MI$JHLJS+NHB*]^)TO$-N%-T%4;:B=CQG?!OBJ9*IC\Z&A/1T=!>4;:(9FE>V M_<3U8*+1R7&K![2B#?/BK?"F\-8RZ/G05=Z0 M,/^=$66HXFL(Z2,Q$/8;3-@>ATB\'Q41FCD^$.#':B#QMZ@7'AZ/2,C'<\JY M2]V( .WE57H@]M\QL?M]O@+P-\_N_&Y/+7#V.T6 ^/]X+?B/W")%X)XJ)A-[ M2E< ]D=B(/4S3.H>AZB\;T0"I;V5@O,??-@']I!0#YF."2]Z-+3;=!AWA1R* M'"7GK+6)BOU?2A08^HX8BAPE#:VQV##P0:;47F>"HXI?#46.DH#6F6R8^8TP MS*S=O?[/63KY<>-TG_6Q"LH8)>GTF4)A6]YI$,8]P@CQ/51"&:/DFB%S*)P' MUH\B?"02NOI(UR'01U(H:90<,V@/!?6]8BE1ZS&+ZP>-8RT4-DIF&3:(0ON1 MK$:)=<6FK'@(6 _=6P3*'B6M!-E%"<%(Q%(MY,[MXH',[/&X'L@D.*37%(2& M R7??(%UE*!<)8G%I3=_;IF@O5 H*N7@9T1X 0C8?"78^R_#WH=C1\E#:VV^ M$NRG+\-^"L>.DHO6VL3$/K ?[]2C7'J>0'O%4.0HN6B-14S@^9GF3MTK^:D/X?VQ1=R59K8VF@8XS?%C.W! M0*9I)C;W:#Q/Q3Q2*%Z4]"]HKV'48\E9S P3LT_V"E$QPJLY5^F@D%&2/;^Q MA@G?*^HB3>UE=SZ/RRTS4'?3J6_D#>FAQ%%RO7JCN.1'6F=4O91_12EH%%#2 M/JCIIL<9&F=VV%OW^I-'MV+&,\H \D4+ HF5VE':0QX685SXF84?_LA6HE%#!*IA#23Q@M>GU>_F2 M'[=Z6Z5Y/X;V0S5VCQ0*'&>)9,A>TZBSA!F:%%T:,D%$;%.J[;HV3W9>7PH: M )PUE$#3*+?WOU'./PJY%&-*M!0T*2[U0W?XO46@44!\AEAC%R4$7R7/+"65 M3P15GF/ (X4B1WQVZ+&',_>RF-2\/?<4K^D($?>5@()'?(@8-HLT/\U0UV?V M3-\30S8]#/'WE8#R1WR@&#:+-G]>#>R)9R;#S\P/A%#:B%-A*ZVA0!ZGA//K M3#-!=7!L.1!"(2/.>:VTA@+Y)J5J9@>U#THNS7RSMC,$VU, "AUQ9FO0*@[\ MU8]UY,7ZMR#Y"C7X[02(V+TFL5Z[$<=N(D5Q)A<)41[J(3V4.^K"2K_1ALG? MF3E5N]=/>6=&-F\+37JH+P6- DJZ"C6-9R=]::OL7O&D0+ <-#>8B3H!QI*L@_6.A M%TVNUP]T2I6;IO!(5^;:-O04OB@"%(?&!_6-0F ,%6&ZZ![YNK4;W'MIBV_< M+_?N5;OE?U!+ P04 " "OA:E4ABX7>V@2 "_7P "P &-I9VYA.&LN M:'1M[3S]4]I*U[\[X_^P#_>]S^@\ DD0$52>04"E]:N@K?6==YPE62 U7R:+ M0O_Z]YQ- @E)_&BA]=ZYM2V2W3WG[-GSO;O9_^_$-,@CII;+9($.W[K/A8^NL:]\U]%A7?!(B M*143H*%5FP^(=MXI^HVQKCRU:]GORL.NNF=O*W+E.3K\'K,!DZR^,M(,,V0W MA]W3>7>>WG_>M M7W0,&F)0X9EK&\Q+[2U:8MU5>VQQ=YI.<= 8&^"Y/ D:'L8Z-3NS/JH^M&A! MM4W102I+.SFA5XQJ\$GPSS[7N<'J^T7_$UI-QBE! 'GV,-8?#W)-V^+,XOFK MJ0.,5OUO!SG.)KSHJU\1QQ4#L/O_RN?)DS> &)[>S;J1X:7=^\8 MR!20#G_;%C!OV@2NN-3H6!J;?&33.PGL3J54K6Y+;X%;C@L,Y:XWHB[S[I0[8?Q\()YX]A8X+:3E,H!5 M2I"4";QO:U/B\:G!#G(#$+P:D26'DRO=A"[G[(ET;9-:6_Z#+2# U0="Q#7] M,1RGZ9YCT&F-6+;%1*,^J:&L,A>50'S3-8U90B7P*W0\'YL 2_6E?<*[:"Z. M7-M$47X/M+4U3SA1((P(SU@;"4.JZOE0 MAPH33\L%C1P,QD'.TTW'8+Z1"!#%0?O(/'OLAKB@FY"(6L (HFO/,B(T9N$P M)M9@]G3V7->P9: SEXB)L%3_U.Q\C*_7XN YNF(JO@"; ]RUM205$"2XO$4Y MJ\^G$$*:MR6&P3IF# I;%LF*$1 ^#%@:Y_/8TGTF@S(FN&DRZHU=5@^TM@9] M0F!A4QP%0LN [YN 3!0!$T2G'\8Q-S4)/& 68!F3O,6Q0ATHM]U(\]MYL$AC M&M0(TA:S;%.W7D+[,E\6\:8!#MMC7$@P--#0B#[ZQB&TF/M%& ^?^+/OA%;6 MI.Y0MVI$RM7__8>\(^WM%YWZ:[M$?$AW;+#\)1T*5Q0 MY^WH>_*>_IT)/'/ZD1/!_Y$Y%&.3B#/AM5XLG!^P:X^@PN:I ?%.C:A@;)@+ ML^O7K\\[5^T6Z5TUKMJ]_6*_GN3Y,M'UVLWK;N>JT^Z1QGF+M&^:)XWSXS9I M7IR==7J]SL7YZFD(&;]2/%^H-X);S+5L=8Y" (?Z=.@N,YR'R]R.-GAX?W1Y.>E4 ][-! M4A1?KKZ;_UAL+$8E^T6DM;[BI9Z%1^3<+A#YK[S&H)S=]OD5Z;8O+[I7*T1T M.7:],42:A-LP0L7,G<@E8KM$+F]HF\0>$#YB2R$ ?F0%#7L:'8![[.I RZ$%N7.;;+R4;XG5%PJ,SCA#VB9+FBF6F;F-#4 M%U6PM:""ER)H:_LA7;HNGETR2,U//S2DW1_6Q6CJH $F$\:--#J= O',2M/5 M&&&Y^AF=DITM@C!_C^JF\+(4\-+/P;ILJ'M88>*8DZ:SLGM6DKY6Z6FC<[\$ MLY:&%Q03ZQ2D:;L@!J+.]7OXM=&>4- .I!:%U)U12:A'/(>IF-MH1 >&R9:#RCF4 )!\RFJ$+W-)0 M^FVW1IY&.MKQ%\WHD6XPX&2?N>F2L#.M-OHG.R7\#] M=4L[Q]W3RM+$(X, R"24_':U*N]6=W^+L'2Z/=(V'<.>,C?$%"<4TXR8\,!_ M;E!V$0ZP_JMBI49L21N:YC+/"SY.=8O)Z$7R_<*_O)2F>>6?KB?*_(PS.9+IMY<]2Y M^J%AV^8 :U$9[-I*% *VTZ8C?.2%>PG)MD HM?7D.Q5)@[S!.O? M?^PJZ.M)DE10L4RP'%IS9D0)?(UN<\_,/$&[?MPWO> M POP\QNHBTAS=479R8,.)'9.?YGQ/[RQ9TR)!Q&1 M-YB*H<$(NP],H&$2A@V1,@5$JL@ :QJV#2!YMY]P'/H*'8-T;SDJGDNH1.@F MOK@ZAREA6C"V@J#.RRC3?;H^>]0^2?=M=2EENF"'?T -+[;%GTI2KOZ_=_^7 MY0.#$4!%= AQ(H5=W,(BVTHYX#JR.U)O;:A\?6U#KI#F49'C9/EQ*09+(]2<^S/)]WA\GZ_9,, ME[=I7E8B/(\6MB,E*3K\%)2R;@7&2+7248EENE;YP'<\;,_?%Y1M4*A?=TUWKRV/Y5RY?@KJ? M6<3UM:3>E5A^>T-]W2(&?9?L8R/6U?=YS 77[J3MM0EQ"WP@4%?[2Y?0?7@U MTE\\<[&T*MHR2^E7>$K6W^-31T2%D,M[MA08/7>2F&'0&$PJJSD\E)+%(*7\ MKACD4I%T]:9FWS8VO.V+/>;#[)L2'A28&E/III,.3N>:GUPBY MF\G#'V53T.[S(-'Z;AB75;X,S.945OI"-]/=UO7I];ADGC1.>LO8HUC$B74G MTX1%['%;O=\BE]0EGZDQ9N1_I((D9Z:M+RO&CR[JNUVV<&LI,!.^E<@HL'T] M];P/A]\^7NM+6+,80EBPSC^KDHP)0\$.8Y_L3^UFZ_K;TJJ^: Z3 M!=\TFL".PER_VNZ]KW*S8"VSWMVQU,)JMUTRM].6>O K$TO'TC"^9:0_):HH MU\"H>VAE8G\[7DI97],] A( T3%"'A( ^<1'&"<[6%^A'M'80+?\XR!^*4 J MAR%GO X0'+5FM M;&_O95K:W[V215FJ_/F&RE1G\(S2X(Y#J@KJBX7,];41*!@S()T#!;-LD=R- M/2:ZP<*(@BD15R-UD?#Y]SAP/00R8XK8GW3 C3)C >70XK)'W8-QH+;44K&Z M1%5QAQ [X[U4C;J:YU=*M4AF*2H9\V.<&W266D85LT!FB_D;S^QG^]J4,_V_ M] M))A).VX2ZQ_.('27H:L,+X LDMMW&;W/]QG(*Q%3"]W&!CZQ_5#K82Q.SQ+?E)]1%W+[DAPB!%N,&UX"0W/LNEBB#,Z0XS&S MVX'QSY]-GED M1!_!;4/F =*LL7#B47B%548Q<35\FXG\P3)NU#!+"<>(1APES MFVB1Q59$ORY66RG@>9;^K"\V= ,- B&X<)@;;+>@,!_-M*QI0X2%#87YZ*AA M?U_F,#,TW2/!MS\462DKU5=8)%2S%TQ2P@;QD:'IP$(J!F8!XR)9[>^5YS$)?G[>U95 MV%3=FKW>A'@C:AC"8"P#A!%O47LE,VT ML"8A3*T?+F(_.@"/B0(&!CZX2/6"L&UA!9TY_@46P=L^)E!"HO%\">/(27"1 M,)W@@HL:GYJ46ZQ_=YM?%87PN,V?6W9QD!,CCS!^ M$5;'6YV=7_Y5XEQ]0]N$)'DO0OP20X/,RU+O6%RR1"):QQ99G,;4P-'5?/N" M+XC*U0-.1M^+\/(?"%UCA5[\]UJ$D30A42Q>FO#Y>_[) QN"-XFJP[8V M31N@BIH8Z6 9AZKB4'F+QWQ%CF"KY'#78&T57J^ MZ*;\4W1[7T6WE;VWI'-\WKBZ[K;?:]DL^D(%?ZO@8:R[03STVH ?.JVO14Y+ MXQZ#-H8P6*5CW!<0L;1_.ASQ0*3L :.@P?8O?/<91- ##)41G7"*00?,X,86 MC!'@Z)B/;%?_SK1EI7%_T[OAK][MCRG-' R@QQ#D(*?D7@=RMJNB9!XK6.%U M4K&*L_=Y0ECE.,Q5\=V\%OA3 ZGM=<+&(+PX6406^ MH+K^RM<4[Q[>B>,WXB)AY/7&[,/DZ)LF?1S>-SZ-;HL-;?)-N; ^RA\N&].' MKT.OV^SMW-Q\_/A!4[H**SW>W[BGG_5K>FCW1];%KMKIW>J?E$>ME+_V M&__A9]<[A[=F6QU5CL_44=G4IT.E,Q[*W\^F1[+R3?ULRW;[Z?SP\^7)L5/2 MJ^71IX>N>DMYM25W3V[IMX[3/3HK3T?_Z=QVKUK#;N6A=S/]?G_!;IO-?NOP M^+2E711W3)?+\MG'AR?MMJ1T3ZK]8N/H>, _7'TZ./!9\O]02P,$% @ MKX6I5%!A5 (=/ A"H" H !E>#DY+3$N:'1M[7UI<]M(LN!W1O _U.JU M>^1X$$V0XB'+K5A9DMUZH\,CR3W1^V4#)(LDVB# !D#)G _[VSGWA^NKDV+AT^\7I^?P)\/_/CUU[']CTPO#WWV8 ZXQV[X$[MS!H:MB0\T=L]=L[L' M/X2??E._&QANS[0_LO+>R:]VRQL>?_KP;?%'?/[3/S LLP>/N6:O[Q^SR*\N M?O;-ENFSHZ.2/F7Y8Y9:9@Z@XK^R>#?]HX?3SU<7[.SBZNK^V^G9Y_3O;Z?GY^K?LY;C=KA[T'8LRQAZ_"-3?]NC@_ST M<*=>\,A=WVP;E@*YY?B^,]B3Y_WIX3P!20T!&1J=CFGW#@@K\%GI<.B'G^*N M@P\1Y@//_ \7@!\SR[3Y09^+7^J5\KN]DT]?;F\>HJ0C?U"A%0!TQ_W(_JM< MKA^=GF8N\,WEGL?NN,4-CW_Z@,LAB9XO;Q<9)):ULR>7-W]O;P,<_7W!G6L,^^FD;;:;5XGBLWZ^6#1K-QT#BJ-W.'N*0@_M]M("2CU'8& M^;UC%<=[?7%^>;J4$_V?D>?#?8)O/,]T;"_O,VWJY8-ZK5)= LPE!?-VGFJ< MM[6Y[7,W_=9/GX,7?SYYGFB;7YK%A.#R1%ML?=\9!MMEE5*E!F!ZCF5V4L(@ M/(+Y.'4^1T)'<(8$!G)OZ+B^Q^Y]U[%[[(OI>C[[U\APX3%6*5T]\ P9@V4,9_-2N5^G'RJ2B*_D*NT1VG MU)%RJ4Q+?+H\>7!\PV(N?^3V"+9IVLSO<]:E<_Y;GO,3=SG[Y?"P5&8MT[* M_VC,L#O,Z. +>"?X^:?[[]].0/'%/XJ%X&>Z^MFG#Y<1I2,DX]UYS7U>]WW# MY7W' C[BX8IZXYC9W(># UD !^>X60=H>.P7O50)CP\>^Z5:JC>+A2%\[^&B MN\-YX>&D+(VN,3"M\<=99BJH876=0+#AP-H9/*@K>J(JX6-//^"A^ MQO5266>)(PY-F-U)/_<:)@Y,>C#F_ ]/ER4/5ZM&CI=DJ.DQVWEB0]?YB[?Q M7;[#6IP9/D-;U&>_5"JE>CERNOASN7RXNI<8VC,<4$AHG-C^S=_WE]\9&>7[^%D.L88Q" J M2W!0GM"6XA>4SM05VA+\V;7@4(&XE/ L%E"D*,A'@#]3AXC?OS$+>N@Q1'7 M3A=_S=J6""; :=JV\TADI8$XATL/*+ !J+XY%&"Z_,"T'[E') ,'1MN0I.DYB)ZV80,- M(6#PBI[+#20Z$YYH^X'("#8K-N$,!B/;]$V.^ WA';KFHVGQGF Y>!-X22(G M/SIX ;DM9CHG-%Q$1<;%3.NX)::8?+&0I>"RM'XK3XJNMJ+F-@#NFJT1L7K! M^CF<$I(BL91_> P><_!8UW+#Y8>FW>$VR3@A)7,^AME\9K9B6RQDG=M$U384 MC)JX*2Z7ERWK^6HY^GPFD>@;QW>?^<:]$T5Y1H;>F=),0KUDV@E,53PS3J 1 M?_ZPU*C./H&(W"P6Y 4+1&;\IDG)B5SO3/!)255+DJ0K.L8)K[GCL/NV:9GB MX)"[^'&^!YS36YV/[!LL<@R8^GO$03\ K!ZS MVR&!\A$Q>H\$X]C'[ _#&F'HAQT<*$?=^>4?\3A;T@29RQY*^_K(>IED7RC' M9^SYI*-/Z>R?/@",&>"V0,+_ +4&+@KL:4@HB!I5.<,_-4J5N:'H":FS.68/ MXR$L<>H:+;-]S&Z, 1?G=^/@J52B/_J@?H7?3$1/(DXZR:*,A71C.(V^$2$1 MU+%4)A]UL][>W-]>79Z?/ER"$1AE@DPV'!J,39+0)V\]N>7HUY;@Z>9)RX!3@"_0 VC $) Q'R MQ;3![C(!Y]+7S_8["+A+[N*!D.+>^X^)(,4"8,5N=X+GQ &+/)BU*7WRIK)O MX$/?Y9Q=P\-]CUV #MQ9_RX:BV[BVG#!H*CJVHM?/84H,G-6SGF;#UJ@G 4O M?P[B$O=#L>S/EM'^P705'-N;%[]!G&V>A5Z"!"7V9KT.U>2MA%K?'*AE(LS\ M0.=P@V?"OM+G7W*SI'@YK+]+)Y$ETY)(<11.DSLE3K-=ZK5W$XXWH4]FO'3O MY)<)B^K)QR6K.3S4RN7:I!]EOB*;7ZP%^+)VU$C=IFT!OJ;5F\UG _\2NIU, MJXH#Z.F\.F'Y/"\:-U]2X0UHCG<7Y)8= %=E^U\-$S0A=N6@B#\=TU%A0;A)CF$M*SD]*BZPC*4$O5U^RRO.AF4[MZ\3( MX0XA,83LZRE59W%HWK^<0@0SC)B)ZG;,WW(A MO=X:>:C0X67\#'7P34+5#II5J[T1FHD%3%WO[Y%SS% QO23_Y1(YJZ[IS90> MN 8.#W#44S;5>N#0UR1H)A+'!I@_48?YRQ2@N>]IM;9LS6-N4/1EWY"Y(=FO M'->_UT>3IP -;_B.P\D)NG;;"]7:)1W[![)L:<3H$T_?70YH(\8HF@ MI+TY:P.ELD+.N6K?$RN.JI;_H\ M-S-_RANJC9>:_SF#O[&>$KV<@Z?D=6&DF9)4+X-FR\69LKGNA8X:HW4_5V^Z!*TIU>2I:&;9?ONH'D="DPF6\I*U [] M#EJB'BE> K3,*%?JUCY# F'>^.L0ROE@HUK>82."C:U03];*'!;06:*<8N,9 M Y8S[*Y"$%LK-5Y)(D!.V'BQT3NKT4<.:=J4G1TDI%,U].I+C^9[XX94H9"L1FT$%93JW'_]U1@,CT^+!?YSR&V/,Z(ITC(/594V MT%>C=/AN4N%W4)@*S+19*D]X#HBQXYJ/W&:ML:HR"GHT4"F][9OP62<$A6-' M )/;[?'&$>C*WSB]7G-7D+FQ!9G55U60.;D*\_O]P^WU1:27Z.^7WW(NPEQ* M;XN,JDIO-( G@# \T6 B*'L?\ X*@'@3D&+! -17O^YR,^24V5=J)L*X3'9D&S%%'V KGU MO72/S9T'(*NP1&/9*-,/M7K:KE]?=9I6JRV8OKQ4:)JU!9.Z-Y*DIK6R[:.D2'84V^51 M?Z=.MG/A;9UUNYH MC72!XW;F!.:(DWJZ(/G-XZ2A+RM;GZ.ERXK,K8;6+&\,>: RL6B9^AH9B]#B7,Z^&:[/SI>-G8IV M5-X8.[VJZ,NN8F&)%0MDL&5GUT:S98H%P\\J M4.BYL')KS*KOQ##$H.C+8?I1N72HZK@VKLI@1U3++8,1-P= MP*90%I)1H]145(23O7$$CHOSMC#'MW[4U,KE[C<@8.S!1@R"4C_G4Q.XBF:]Q=W'^_6M;$L$TJ*;OG/#(CD*J+$^/!:'I8%:O+58C97K,X[U0 M;.#(.8.U7,?H,->P>UR4KCLNB&CJP(T5G4/'M"D ,1*4E9P+3E6?QA 8DD43 ME#6Y-A9B#54VG/HY?-OB-N_B'&^ %M@%01/YFLS #K= BKECN3A\DOFP&!4. MX'$0V3UB=9&5P"1M]^-S-X&^)?A#R\!G^&!H.6,<>LUZH4QUW)YAR_)L3R,@ MY,_:D>7<65-3%SN>9RF-\;C1Q@_4F^(Y6/YPO0!92R[W6>_PO57M]M=_;4$9^I478'XMP9;5WIWLSH<:^^;R@P?CIS \LZ_4@N&-^?H4 M5Y>>*#H?')7*9@R-J5D%I3E"V2N M(I4A.1&*Y80AWUJL1UVVI0=\OJ2C,(&_TLV8'!F$8CJ HG[SKPA_#IM"/!&4_,)/''$3>5=&JMHB=C:>Z^HSN:>CE- MF1%EQ(DH(T-@]+Y21I*D5BS4,T@MT0XO0FI!\SMF=+M@*@J?Z)B9 W09DO=2 M^$M5&$Y28W;<#PC7\'G/;!<+9C@M&2F7_QS"*OA&9^2&GMBAX_I=,$0=>D?' M[)D4<(_X9B?0]?1XW^$NWK>I\;[:JXKW/2]0(N(WU.%-E@BU*3?U^PE=ZE@A MP-L(Z<2[W27J.[5D!H&,HF356@5\"A;U^X:O(A_4*]3E?6Y3XH'*O!#]/\/H M41"+0=8I\AUDN$BE4)22T!4+\(K.J"T?#%B;W)MZE1:(;(PG!4G)(DBCL0[E MGVKLT?0HDT,&;XS.H]-&,0_OZ+G&0+S#\?O RS-?6RQ@<-6TO9$K@V$>M[H' MZH/D-B)9&>'6%>1!BN-IY]$ \'I<"S^['PV'%LD'$6U*Y$,"5C!<1:%>C]NP M61F5 @HSX4!&P=X%L 8R ?$3N,]]YMABIUV1#C(C"S?5.\I%F*QNG6&I[781XX>H_F]8X'*%DLB+C2MP]XFA\T ^')] M6K?$#0>^HJ>")IL=\UOEU9DKXK>Z@%\E74Z_ED!;^7 3 H^'2QO3NJWDNOY@ MGZZ7YCB4I[:-^KB9.+D&Z#:SHCBEC/OQVX(X882\$26BH6OR: 7NSZ[B\U\ M \[4U$NU63/?D!$6"\TR#A^<-/4MPFU=T_LAR9N"':,A5L!Z@H1%E0U0(*R# M!;*"]?8!>%@JJ-$%'DLN8>2;EV$00W%.X.Y9G-=RGF"1CND"(.SL]H_+\P/] M2"RV(^!M(^ 4\6*589Q AL88)WD121]%QAC^ JKBD9J?FAZ762R(>9F_5$N- M*8])PD;RA 7+Y>B3RGLF%QQ>E)3;9?4M*E)3?6WE-04Y"\Y[M#!?#]B\;>4DQ*Z4%>6S;0.1A!N M7>J8GL@E 0.;R1G"F*,4YI$8 V>$J42VXS/0$)VVTCJE689)OR(GRI-9,C(Q MBI95Z5+<,@$$B$&K#*DV3(E<^/KN]NJ2_ZL?O MM3"=!X\ MFBPOZ@)P"/ A6UEX*.'D?N#C\7@5-S:&5H2]CC(.G-']@'F&X66 M\DIS<^!2*4+>LG&GSZBIS]2Z=X7VNYR;7<[-+N=FEW.3:R9*I52OI7MGYYF4 M,'7E29D)TW^TXK2*W0YVV2$9X?;]J[#_V-JS0_;U]/2-]$KOEPK!/'7@RX5 M3TUEF0C!BB/NN_Z\=.C/[HLZ+>R)?0#GBV,^&5@#$_B\9T4;(S$B$:I)VO'+ M;LV[F ^POO,!;JH/L/'F?(!T16^_/US=WOYS"]U[0&63'7P8Z?N'QYR1;SG. M#Q%B'EF6B)[AQHN%2>E 594H@6$TYR_@+L+5U^(8IK.X 5BYX:)ZP-P#+Q4(<>HUAY]<%%ZJ M 5.6"S 6/1[)8 EN)F^4'5TH2.4_)F#H='VT;N)_)VVUQV1AY!613?IR&WW M,=4*W9L@),TAX8\P2E%_D69%^3*>-QJH0E,J4P12,)V19Z&;T8;-M'DGT=VZ M6$A7'C['K1KUF0+S@H-O@Y#D*D/!P^:ZG4#JP7YQ Z4,K23*3)/,-G739EVR MF)MQHCLR\"M.M[L347AAQTZR;O,R"(BS9;D7-:P^Y8""IS['T+\3=)M5)*F\ M_.]3(]Q>XE-2QJ$>,>Q)4%1+C1@^@MF4I?P1\NF[X/9G499RS7W7;'MA^^%P MQY-V4:V\2V573#]7N5(&UY^7X0L\S8IF?1/L#D,GR$J_("O]$UGI!84KXCV6 M7PH2)D/2,4V#*.J:9,)1%\(PW4/0V%0LGU'Y-@F?-6#T&R7 A">=0NB++NIZ M+N>D(K!JVBWQ H@G8#4_%G-Y$J@%J/7@V(I/'RZSP<^MPGK-)Y9=>Q37Q+;Q M_.#T:I-/;R.!_^]?]#3!O3[:TA+Z\U:3F;0+MHO,RJ7*JZ*S^Z^_&H/A\2F[ M$.XR=H>4)HPS[7#;B*N.Z>1@[C9*U7>O7OP\&#_QM*0EK>GE;3LM8 !E.B[X M2^W5GM>9X?79%\MYRE04MIA_-[7*%#5ART_MWQ10A%MV*EM.W?>I:N5VY'N^ M[(2X'V0N;>=15O4RWKXJ]A?8$BE\S.+.1=@%N5(Q?A5NX3)'//TW,"DFW8,# MLT.CB0)47;Y XK5)%UWN;L\KO3U5[6C[?"]IB+>0MJYE'>@97K"MMH*;RJYJ5E^Q725F M>P>GIF9\?Q7-]O=QFJ-2S+7:MAUA8&4U*K6IOO1-@WX-"KI>*PL435+*@WRO MU>2>+)(/UMCE@VUJ/ECS;>2#!62+W3WP 'N.&&%B^')ZA,N'V&[ ]K/+[MHC MUZ7B1EAG0$TYG"Y3^5<9>4S4TES40RZ6TQ1T3B\6L YP('1@K,Y48^BQYI#^ M;E)G$&P_4V*G;1_[?+BR\FQ@C%G'[':Q-0@\[XJ&'QVNRAJQ.P*S1Q2XA[6Z M1MMW7.I7CEE #C87 ?U@Y/9P5@?(6"#]#KW]S*"^-H8[9C<. '+'>X9+2WYQ MW"?XZ\&5X_S ?]^'N)7)31V1]A,%^SJ,RBN=IE(#,<((SX(9K WH"'-"!(V;_%3P2%A*&[>N+!4K= M>31,BS*& 2/Q%+LGWO) %H6]7\1!P@%9LGS6DXDC^R253OJ^/_0^?OA@JB,O MM7'!$M#HAS[0Z8<.[QI 3"7#&_Z48N=]J5B('!DE=+4XZSL>Y28;> F YHB% M@+YB,2*=1Q/0E-%S0Q&K&*I"-<')Y$"5'M?B@$[$&ZS8 =HV "'-C]4R,TJ# M$KMX@ N )1(_\(6X_20<< 0A[F:C*'*W%5Y5-;0A,P*GX@^3''SO #9V(+F* M>$$63C>>? 4*#P!K@F&(T0)96"82Q:\MRWGR/N8^8#Z<^T$Y_5SQ41>)7IM+M]D[N.-#RQCG_I9DA?A$$JK7W[-JK7&@'Y9K M:Z"@2ADHJ%H_.BCK^I(I:!WM+BY]9/-B*AU(46_4ZW'2N\;.".0+SC1!SI\M M(%ICUORHUP)YLF55 DM:7-HTGT].6R")A4S,MX9B&2)KOHQ]X6Y6;3Q(,;KY M\_[B(SN[? ^4 @J#')^CQNL$,Y/:PC8 =1J],K+V0(RB(PT%R$L-3,+.*F R MDG)$2=A&FY3W@6G+YB68#?_$:7$NRR9@8?3KN%ZQT.X[\$JJ(8-W^7+NG988 M@T=9_NTVSKT#2$#'HD_)AZY:GF$J?\\E8*-SZ^1H*=NF(@-*O/*0%8#9&1DS MA2:1@8;,(_4V>>H[U"$%'Y4[!?T++E'VB"D$0\ZWZF!VNC7RJ+D:WCE2) 2$ MD1XS(U"YX,*Z9L3,BIZ4AC<930I\.AHVH!G9,(0G#IL@(:7'=!'Y@#XT/>2(KXN?J.5Y[+[MFD/?B_Q&ZGCIG\Y'HV"1 MW8_:_0F(51.P#!OQ$9RO-S*%A9B@6PV^@;5 00N&?:EY7AFCOL(Y8&K85V:M MAQ89]27;5(:CQDHL<%>]%GXQ, #3\/\@: P+>8&Z3&.2+M3S&,R2-I98N.J" M_35R30_OKPC?4-].-.CQ8?VH'/0G5'//9,]:>+AO#CUU0Y #(V]YFI)?@"VUT,X"0GUX M,GU0"L2Y*V/GT_>3IZ>GT,(1,3EEO^1\QMLL,2.+@]A$%PG:04NJ.MQ-NHU_ M_?E$+PED/[][*BH[R9))U"M'V&X,)%; /_*;P=!4V/OHVJ5S43+-^2&RMDB"M1@EVT@#>"RZ'<4ND@XJ#=P&\%C M6&P8ZZ 6[R#GJU;.N>TCDIV@W+M8ZRC0QO\>H=XUX*#5D78'.AG* ?@>Y'A\ MT[# P$ ^*^LR8X1DF7 NXB%TB :N:6/Q/N93_I/^Y!@9!9@-_=.JU;E08,!6 MI I1EV%HHL3^S27M*+>LV!_YN,G5.^ &#O4,KD>XT=PV$B ,(!@'6,-9EVW" M&.YGB&%&*CXF^".;AHV"+CU _2^8.! ,&F"9O "7[W ?;[DM* U/&O1QTHY- MT+F^GIY^$\H:B&VK0[]H<8:>4/0AHG&!6B[6V_H\\*<-<$*"Z,)M@3XAFHB3 MRY+6DZC4$I<7:(MST$'[9@MXCTZK&? MJ/5M4C:E1S.[T#K8%QYQ?-V0E2XV MU[JY"_=M:KCOZ+6&^Z:H0CO5:R6J5R57U4O&2O>ML+551"21=V;HPD/F$#A6 M-PB8*6F#'0QRDBY@S(*AJUPM"ZF!0FI[\XE9Y>@(%@V[*.2H2':4*[=.T+D*?E.4H+[KQ:37]^UBR9<(>R3.S\F%<7D!B9]X%W):;3 M1O,)*,$E/A\$GU?W2CY:BK<*26;J1+:8WUG$4+422X(E#(G<]A(8)+.$PDL, ME&PY0OE .6UC%O23[:"5J; OZ+J^_9IE-0_-,I*V).^=$NHR-I5)DC.HD'+C M9ND>@HD@S<^VN07?ZLI4.DNFT@G^%=$LT1]IA_!3;% K%I!A8!A@9.-0.D<\ MP3%4Z&N!Z$5FX-A*+W4YBML@/+!OOI*/J,+-N@ M3^!S>M;E- E$M*QC(G:&&8[%PAP]ZV !7^F PN ;.CZ\ VD8;B -7T%^@A1( MP5+U0KR/+34N16F(\%"[/7*%RA-D_4KW)%S^9!)IS/&?Q&8XIF4B6#.[#(H4 M@[#1H)@$%W8:+*TCQI4M%5?W\E,O0HOP@_\Q[!%>8SE&5U@H,G$ MYCGI?8Z8$"G2V>F[@#"4QBDSJ]4=B[P(EPG 5 '%/*6-Z EIMU"Z#MZF$:-&G4-T:RET('U*IQRT:ONI(FS!Q M 4*_T-#QJ/.FIB0701+MTMS&!A9=S%O%OP]-P:/)="9)IM$;HI\09,!+0-M! M.6L93_*6J"LN!0\+#B!^.)2CS_D !RY;_!%NUYN\14@?/DZ,ZLD\)BID$*G& M=$J>Z$D1^^-(+8,6T6J&+B51]6323\!Z\7T \ ^0S\C3 MS4A^AF$).<+1XR>H15*%H.@DAT0MLN<: SK5%I?,%5/#PO0F6[TL9*M2'P.- M,S#X[D9 3'JY=: WA<5.]'//@9%0RE:QL?I1]5 3\[LXCMZ) M;EV]7JU:.]"9[QH"+9:!VP7-%!#T"'L%'F3SGN,+-0<>LSVC+>=X/?23>RP6 MO)$WI#?B&IC![Z!39"2RY/$>P+GRY1'U NFWJ\Y&G9"$J]X_)7AVM N>;6KP M3"^_UNC9\V_26_%!'.;A@[@-4EQ)[1"F;"2*$1;.3+3]MAW?C14-P58&9C)* M$,S!)O&-IQ ZW;W$E&QRKL*1(0.!FT=* #PZ,$<#X4W&PH'OI7OT(@\&\!QJ MFC3#727 1B5QD'0;9M:J]%L/$":&AZ#J$4G&#?)^@_QI*<^+A1Z8#: R580/FB;*2/ Z0M#HI5FL<(Y4% T5+-)C>Z 8F]Z MOBL#6D$H.0QH)K(!XWV""1F+7!>$7? M]D5 PQ: MACF(U^>HJBD$7+)!6EW!-HU?[2AY;DH6XQ*H90!U0PK*HI A>YB=B(4+J(_ M3X8GPP?"?2A]M\6"G&*Q.YQ<#B=3KTMSG2!PDOZ*"B/QTA0+E*8%=\HF&YXY M-'<]5BQ(U8S!3X/K-T1--I':+:*O+8Y5CAWTR'DCT(!5>?"L<%.0*9[OB*02 M2U$S<9D6YY@S1>UJJ-H4RY<==T#Q9XH(1=M,[&@W'\:"(LBDC'\E4Q($% G& MB/@)*"LF51P$$@F_0\VX6%!1:HP[Y#];BPPP6#:6-8>"^V'D8A^A@(Q0!Y?= M>"AVGUUSN&1=>I?S,DNQKN>A6&-QCBV4#J *AQG9) I'<=OVG9::.RI)ENB) M"#._%+Z%"!P!\_@C&9-A02TJTKD@%MW;;CM?FY;4>.NL'C?=IYD"#V-N^?LV?P9V>_^[P[HS_]TT+2^ MM#N@77NFH2'AYK:7_P-R&8 #VG=&()__Z;@5?:J5&18U^I%@6!E'WD1=&#X(]A)$D=2C' F_,@GUAG"^GG62<0C J%S.$ M)O)'4 >C6D(*;BS$CT;>5=171/%]!U7'G/:@XOI1=0;3"C +A4RI2*CRB4>V M3)%$3@W20".(A.]FC%M<58+CA@:@+VW5 0-113%84@%%J[QB(44+A'94$"GU M8!3)Y1%)ZJ*SH#MJ(XT%:63XH\"5A;\*$5,NBP7,YHVG MS)W)[HAWM!7J*(!+-0_^R;JF%;.P6.50,D[RH <346'+5(8946!?6Q[$(I'B M[=%S7J+E-'*M&1.P!P/7-4R3!6C;(]F6I"53K"@D,E1@KG1 M[L\5@U@;*;UI/;J9BX.:')_.DXW!B1KL.5X'%E,Q4)T[ZYMV0M4(LXE%0EXV M,4WSL@(/I21"X=R*\U^$*:BQPD5B[PX>BZ2-BF(JZEGSA4O/R2UEK:D)G7,6 M0 D7*9:5;(#-^$:C,$>Y%$C$8M]#8TSZ[1R15]G@BU0$(&B;^Z2HN#STYD=[ M1)&3'=>6264]%P/?@\RWM] NP<0X4,]_.2P='@7&AA&:=.+0E3VFX8.5NGH0 M4\DI[5*.*8X]K N;#'Y0KLY<6=_<0J#5O3SVVBE9;'IYE\:VL6EL^FM-8]O@ MB_.&53"]G(=X0E&ANCM(YU*@0Z&"CAE/TKF465B;FWMF%16Z866MW&HTVR6_ MG83^A@0&J:^3R+U@*2Q3^S#10C?,P G[*9="@DBS.D997?;B0(86;1 MXAT=PJH6;8&6"SF2UMR]&[1H\X;%5'UOCJ+%W>:+[>=3R!?26 MW0_G_N%J&G?-,#7TG:FQL:9&Y569&A.&RGT^.3O]_G!Y>W-Z]R>[N7VX8'<7 M7T_O\'C8E]N[?\-?#ZYN;_^)_[Y_.'VXN+ZX>;C?]#[Z\']ZA480JORBH-Q< M-OW&N'QD@M; Z'!1T*B"::(C16SDDT;%@ZARH9A)"L/(:A''$RC#-/I'^C:_ MB6+%2$DDNX(_Y)RH.TY1K* T\JA6*A:^3'X/M8%01<0J.S28]D6Q55EZ3L)=@;61J\".M-6AGN!9?754TP"T4\0()CN1 M;4]3 H1VJ<4BD:3*'&>\+,C<3RY^3-4@\FD_,R49_8,XZI*:I5->'!;]HC\N M^J9868\H/)A:PQ #,VYR=V*.J2CR)M^-4'7OT9T\<[5G$"/H^>US5- ,^ MX- HSAPL$!2M%PN I7 J0J1/;;2L"(]7-2<$?5&.C@@&1%@\,=2!BO1MVWFD MBHQPQ@.="2X6YD]2^H%E4M50M(<\7$L+]Z,N9+MO6!:W>]R+N(%EMMS9[1^7 MYP?Z$4@TN\,'*"3D/L6Y:F'PG*I$>&^LJ;^9;19B0,:(32Q.QL1((!U4PAU8 M4HMD83!*XQX,N2^RG+C]:+J.+4N?,,7#Q'@@MEM(MJ:AH+\AO=7 Y[EH/B + MF@0O\D@_-\(F!:+U2Y .VL%"%&@GDZ379+VT:##?A=P$;U@]H9TZ,C6?YITN!0+\G.Q M!_6Q>EIRDM3'L,7D9Z++2/+3L'5+\AO5S"@%B;(\D^]4_6.27P!RDA\)AUCR M4VS>H#["^TW'+9 DBACQKHCN6MC]P1R8V"9%*@$:=F;H4TL#ZN%E6=,.0ND9 MA'QT!N8[+'*&6A%)#\:JT RM $@2]-D^^V$[3[;\FOZNB>1UT1M*N :,^(1/ MY/6I 9^R[3IV*Y)X%+T93&PQ(;POD[&%F3V(IPFPAEH'MCI2NHL%QR.$]\>D M*#+:?21QD>L4G0%2FTW.L90I+81$Z;L2,,&)X8P== MJ/B(8+P=$&'N6+!:#]0"[%#8AI>*#F&CL,5-IH0*^M@$I ["+^CP%B_&C(6ZC>?9BW'240)><5#EY&%M<%TN/1^GRO>376S8N904*,4.7/)B)7\ MDQV @IDU3'3!=6GLJ&Q%0HK(L>B0$@I.S'$+Y%>$*0=BC,@3.]03?<+/R#S MEXOK07L7*,$S"ZJF@Y(,C UWNYA?;\ONADIZ)'>##4J51F2IQ324XWA' M*R'YY#V1!5D^^0BY3+D+I_?*647B^V%"B:2?IHY)RO8X2CU D2=:SHSC*?32 M^!GVQQYLDV01'!))N(R M"6[-P?#\7L/K4<I A2R] _ M(RR&_S3%T.J,1X\3F@^(/)H(1V8XF9"H2HO$^F(AA/K &Z(K 465;)45ZOVJ MBX8T $<^>5\ 7"OP7<7L6 -NO70D"6*4#R&C3'0,"V.MZ$XABM!"4B"=!XD# M-ZK%,$)< ?T/H!!Z45+I@BTIFVH*S8/(E$#$H'H[4 MD[#0D\)'=-1X=5P 3 M9;=9C=9 C ,URR^<2*D&A0FVPA8G:O!RX+G- 2=BA MXN7R=EB3$"3RZ^6#?TH9TO+(B:\>\=0S'CVDX?_^BQ[%Y/]PYKKJ0S=]\+KH M#QD=-"@,[TAF!:D0*'-&)&C$-7"FV36:+/D&E!@_YHPI578QI8V-*55?54QI M[X3RND76J>KT&TXR0^5;"ZSMH.D3/2W]7_$!9FYHB9)[,,,/H258 3V'#9>' MD2;$U'U%:7J13 3D5']CJ;S9':MYQ:0!^L8/CHD7S&E94E:1#3\:THX(,"R9 MHAXA$V^K%K2'I<0I:4)*J1Y1N#2U>QEP42K1D^G1Q)HV'_K$#&6K2MFXE?S2 M( AS=0/E/Y%VM^)NQ%MITRW%!=N"H;H!*];?8_H[9O(#MT5ZG)#0+ CMF$^=\2UP![L]N M$>*;W_:.8IG7!R*:BTM9G;V3L\NO-Z?P[-VWV[M3S )))CIG_"9R6AFOJTY^ M75RGHBSIO9-@LDYX_$M @CX%+,#"[?6W4]S_'Q?L_OOU-:;"W'YA7RYO3F_. M+D^OV-W%_?>KAWNV/[+)M.6=]RL%U_/'%I 7NE]1JY1TI]C-9PO]*CI0%V4" M[)WLGR,=4D,T-9[="_2*(/]!15\7W4H48G41)NTM>K-?0%2->8E*I34]4!WY MM:@CO\ Z\M41]BP87A6B@^K\U>-75<6%;\_W-L:9_,3+-B?F9]_:7-$S^W68 MPK254.O;#/4*+O_)^.I09&JW%N_XD+I"A M[\Q^,&O!'323%LR5/C9XGSMHWA"6=^"]I%W]3P7_5 M_&)"$6GMW00QD["8,]Z[=_++A$7UY.,2:]6R5C]J3/I1YBNR$;T.X"M-K5RI M;2GPU8I6K32?#?Q+2#>+.&6NTK)OJ5[6JK7ZIO ,@*:B'VX0--7#E&J]/#*8 MBVL%?7)4)Y,X[UH6+BI:K9JZ'.LZ&+BIARGC87W U!?%3+Y$,MUFR22B&YH% M&U3*BB*97K-]=OY!<$BZ\CS.$PSD-5 L[$8J1ZE+LM;QTBSG"]&7G*C M9[@FLB2!+(FD4K6["=KKO'Z[^:%8P$66=2\/M7(YI1SF^=IU;["L'37F\6EM M[09K6KV9$G4+OW:=TD] 20R5?Z5\$*]7-U)ASA&=@I$ M'"'[>LH*6AR:'**3^=S^3U]N;QYBW*MK#$QK_'%6LD$BLW O[/D;M$^E:1C[ M^GLQ#^/3!WQ5JN?8:JD@Y0=YCDY]J.GE%.??SEN1"SY U#=3NLP;Q@=H!HV4 M%VE]*O6+ EB3FDJO6ZO'!ZRNK@]:)?;%$DVR M1'\ +"N2_5!Y:JY*HDW6)O*,'33K":KF[1.8Y%O<[QFF[;UGV/\Y43R\:DA53348>U@5)9 M$"MKB0S>RX[LE]@.81,Y^@Z:]4B[RB&2QV6DJPXUDPB;_1RH[@XT FGIMRF5 MZ;BV+)X%\[R6!TDCE9JP;G(YYRUL0HQ]3$:FUR=U9B7D\>N@8WC]8_'\9EUL MO;PQ"6@OQM+R*6C_LVST]1Z;'[G8_ B4&*=M$JNA]D%A R)L)0D6WENFKOUT M;=1$G72#$;3.6*\@O#.B-M%5VNT9MM2L1:LNZON([0$MPTYN;$LC]7,]_DH2MO)! M1ZV10[967O=WE["PV]CF>TPZO.T(^?!1M)$3_:33;_TFASDF TS[Z-9_GQIC MTQJKL32;B+8=-,LAJ8R"JPMLSNNX?O^9>TU)ADS.7RTOVXLU'QR5RK*C._/! M4:\N6$NZ].K-Y,31I;NIM$ICCO#6BGQF6GG1(80,$>3TEQXU$VL0UV&F<4_9Q?7GU_N#AG%Z=W-Y:0YY;NJQU<$ MS:[J,:>P8TE?-@^9&Y9RJ;PQ[8WWRR5]#A[_!DL?@6(VIKICLZCW:(5B\,75 MC^:N^G'[H'E#U8_ ?SY=+\Y0_K99H=C60F>>T,;EE&U:KMBN" MS$4_G8-A.^]$+BV>2XU7,B<@)VSDD*:>%W.8A;]_DQ,%LY-@20,4 1H;[K%] MTV9^WQEY8 9[KR6YK%K1M4ISETF;P$I-UX[R;M&^_5BI'&GU]"BY;1+S9\Y@ M .:BO-'.R/=\N,U@ +S2VZTWM5JZS/&MT_'AH798>R79ASG>[HIV=)CSV))= M*L^;@2;GX-6L6Q0=]_ /=O&O[Y&V^ZSJJZ] K6YKI6;.2O.6XV/ MIJ8?YMQM:>O9]C*\43NN_6:@V02N'21JOS+^K1\>EM+]:;>37^6"C^I1*8_" MODW QW;P[P\/IY^O+N#OQ<*G;]%K*YS5'_1*^=TL!_? <'LFO*8M8EO.$_XSD^WYD M7C2QB7)7J)_,K__5K.B-8T\X 3!U3LVNG3;D%AXSX8^_'!,^!##\$3H07#YT M7.'K+Q8 %I;L6*,:6K&1)\%-3,BES+VV,[(Q5Z+$'OKU@7GL'&+5O/M(VAH;G,\<%?(P0.MF::XSO'7*WZ[AP%&UZTAFY MK(40<>:- M6<"#0F[N"^]7(_=P>J.VV.4L%KQHV84XCDC9!=MW7/77%@S@W#D>& ZB1Z/$HU.' 6;AF M^WV<3[ );,*>/MY:8\;'-D M4$L! A0#% @ KX6I5+_JTI#]"@ @(8 !, ( !3P, M &-I+3(P,C(P-3 V7VQA8BYX;6Q02P$"% ,4 " "OA:E4A59@55(' #- M5P $P @ %]#@ 8VDM,C R,C U,#9?<')E+GAM;%!+ 0(4 M Q0 ( *^%J52&+A=[:!( +]? + " 0 6 !C:6=N M83AK+FAT;5!+ 0(4 Q0 ( *^%J510850"'3P (0J @ * H " 9$H !E>#DY+3$N:'1M4$L%!@ % 4 , $ -9D $! end